ST
EBS icon

Sageworth Trust’s Emergent Biosolutions EBS Stock Holding History

Sageworth Trust’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-46
Closed -$2K – 478
2021
Q4 		$2K Sell
46
-154
-77% -$6.97K ﹤0.01% 585
2021
Q3 		$10K Hold
200
– – ﹤0.01% 549
2021
Q2 		$13K Buy
+200
New +$12.8K ﹤0.01% 520

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Sageworth Trust's EBS Position: Q1 2022 in Review

Sageworth Trust sold out of Emergent Biosolutions (EBS) in Q1 2022, closing a stake of 46 shares — an estimated $2K sold.

Sageworth Trust first reported a position in EBS in Q2 2021 and held it in 3 quarters. The position peaked at $13K in Q2 2021. 255 funds tracked by Wall St. Rank hold EBS as of Q1 2022.

  • Sageworth Trust reported no remaining Emergent Biosolutions position as of Q1 2022 after selling out during the quarter.
  • Sageworth Trust sold 46 Emergent Biosolutions shares in Q1 2022, an estimated $2K.
  • Sageworth Trust first reported a position in Emergent Biosolutions in Q2 2021 and held it in 3 quarters.
  • Sageworth Trust's Emergent Biosolutions position peaked at $13K in Q2 2021.
  • 255 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2022.

Based on Sageworth Trust's 13F filing for Q1 2022, filed 6 May 2022.